Artificial Intelligence in Drug Discovery and Development

Abstract

Artificial Intelligence (AI) has recently been developed into a sizzling topic in the area of medical care industry. The biopharmaceutical industries are making efforts to approach AI to enhance drug discovery process, reduce research and development expenses, diminish failure rates in clinical trials and ultimately generate superior medicines. The accessibility of immense statistics in life sciences and a speedy development in machine learning algorithms led to an evolution of AI-based start-up companies focused on drug discovery over the recent years [1]. Numerous remarkable AIbiopharmaceutical alliance were declared in 2016-2017 that include Pfizer and IBM Watson, Sanofi Genzyme and Recursion Pharmaceuticals, AstraZeneca, Abbvie, Merck, Novartis, GSK and Exscientia, etc.